ABCB5+ MSCs (systemic)

About RHEACELL

RHEACELL is a German biotech leader advancing a late-stage pipeline of allogeneic, off-the-shelf stem cell therapies based on its proprietary ABCB5+ mesenchymal stromal cell platform. The company's lead program targets recessive dystrophic epidermolysis bullosa (RDEB) in a pivotal Phase 3 trial and already holds national marketing authorization in Germany for chronic venous ulcers (AMESANAR®). With over 20 years of foundational research, in-house GMP manufacturing, a strong IP portfolio, and strategic partnerships like the 2025 alliance with AOP Health, RHEACELL is positioned to address significant orphan and rare disease markets through its immunomodulatory and tissue-regenerative therapeutics.

Therapeutic Areas

Other Recessive dystrophic epidermolysis bullosa (RDEB) Drugs